ArticleBMC medical informatics and decision making2026
Development and temporal validation of a machine learning-based model for predicting renal impairment in multiple myeloma: a single-center retrospective cohort study.
Article in BMC medical informatics and decision making, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundMultiple myeloma (MM) is a hematopoietic system malignancy characterized by clonal proliferation of abnormal plasma cells, commonly presenting with renal impairment (RI) that significantly impacts patient's quality of life. The objective of this study was to develop a predictive model for assessing the risk of MM with RI.
methodsThis retrospective study included 1029 patients with MM, who were categorized into two groups: MM without RI group and MM with RI group. Specifically, the modeling dataset (Cohort 1) consisted of 792 patients (401 without RI and 391 with RI), and the validation dataset (Cohort 2) consisted of 237 patients (119 without RI and 118 with RI). Eight machine learning (ML) algorithms were assessed using the modeling dataset (n = 792), and model validation was conducted on the validation dataset (n = 237). The predictive performance of ML models was evaluated through the area under the receiver operating characteristic curve (AUC), calibration curve, and decision curve analysis.
resultsThe optimal model among the eight ML algorithms was XGBoost. The predictive model constructed based on the XGBoost algorithm, RI-Lab6, incorporated six features: NLR, LDH, Hb, ACa, AGR and β2 microglobulin. In the modeling dataset (cohort 1), RI-Lab6 demonstrated an AUC of 0.99 (95% CI, 0.98-0.99), while in the validation dataset (cohort 2), it achieved an AUC value of 0.98 (95% CI, 0.96-0.99).
conclusionsThese results indicated that the RI-Lab6 model possessed reliable predictive value for RI risk in MM patients and facilitated early identification of RI in these individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.